Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 4 May 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021.
Under the programme initiated 3 February 2021, Novo Nordisk has repurchased B shares for an amount up to DKK 3.0 billion in the period from 3 February 2021 to 3 May 2021. The programme is now concluded.
Since the announcement as of 26 April 2021, the following transactions have been made:
value, DKKAccumulated, last announcement6,212,277 2,752,287,10126 April 2021110,000454.4549,989,63027 April 2021110,000457.3050,303,01028 April 2021110,000453.4949,883,95229 April 2021110,000454.9550,044,3143 May 2021102,500462.6047,416,842Accumulated under the programme6,754,777 2,999,924,849
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 5,657,389 B shares of DKK 0.20 as treasury shares, corresponding to 0.2% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 3 February 2021. As of 3 May 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 6,754,777 B shares at an average share price of DKK 444.12 per B share equal to a transaction value of DKK 2,999,924,849.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes